Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination by one month, moving the termination date from May 6, 2026 to June 6, 2026. To fund this extension, the company deposited an Extension Payment of $34,330.96 into its trust account for public shareholders.
In connection with this move, Aimei Health issued a zero‑interest Promissory Note for $34,330.96 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $17,165.48. The note is due upon completion of the business combination with United Hydrogen and can be converted into private units at $10.00 per unit immediately before closing.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination by one month, moving the termination date from May 6, 2026 to June 6, 2026. To fund this extension, the company deposited an Extension Payment of $34,330.96 into its trust account for public shareholders.
In connection with this move, Aimei Health issued a zero‑interest Promissory Note for $34,330.96 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $17,165.48. The note is due upon completion of the business combination with United Hydrogen and can be converted into private units at $10.00 per unit immediately before closing.
Aimei Health Technology Co., Ltd., a Cayman Islands special purpose acquisition company listed on Nasdaq as AFJK, reports on its blank-check operations for the year ended December 31, 2025 and its efforts to complete an initial business combination.
The SPAC raised $69,690,000 into a U.S. trust account from its December 2023 IPO and concurrent private placement, after selling 6,900,000 public units at $10.00 each and 332,000 private units. It has been granted up to 36 months from the IPO closing to complete a business combination, with monthly extension loans funded by its sponsor and United Hydrogen.
Aimei has signed a definitive Business Combination Agreement with United Hydrogen Group Inc., whose operations are conducted through PRC subsidiaries, and obtained shareholder approval in November 2025. Closing remains subject to multiple conditions, including Nasdaq listing standards, minimum net tangible assets, and completion of a PRC CSRC filing by United Hydrogen under the Trial Measures for overseas offerings, which is under review.
The filing highlights significant legal and operational risks if the combined company’s main operations are in China, including evolving CSRC and cybersecurity oversight, foreign exchange controls, dividend restrictions, and the possibility that PRC authorities could delay, condition, or restrict offshore listings or capital flows, potentially affecting the value and liquidity of AFJK’s ordinary shares.
Aimei Health Technology Co., Ltd., a Cayman Islands special purpose acquisition company listed on Nasdaq as AFJK, reports on its blank-check operations for the year ended December 31, 2025 and its efforts to complete an initial business combination.
The SPAC raised $69,690,000 into a U.S. trust account from its December 2023 IPO and concurrent private placement, after selling 6,900,000 public units at $10.00 each and 332,000 private units. It has been granted up to 36 months from the IPO closing to complete a business combination, with monthly extension loans funded by its sponsor and United Hydrogen.
Aimei has signed a definitive Business Combination Agreement with United Hydrogen Group Inc., whose operations are conducted through PRC subsidiaries, and obtained shareholder approval in November 2025. Closing remains subject to multiple conditions, including Nasdaq listing standards, minimum net tangible assets, and completion of a PRC CSRC filing by United Hydrogen under the Trial Measures for overseas offerings, which is under review.
The filing highlights significant legal and operational risks if the combined company’s main operations are in China, including evolving CSRC and cybersecurity oversight, foreign exchange controls, dividend restrictions, and the possibility that PRC authorities could delay, condition, or restrict offshore listings or capital flows, potentially affecting the value and liquidity of AFJK’s ordinary shares.
Aimei Health Technology Co., Ltd reported that Nasdaq notified the company on April 17, 2026 that it is out of compliance with Nasdaq Listing Rule 5250(c)(1) because it has not filed its Form 10-K for the year ended December 31, 2025. The report was due March 31, 2026, and a Form 12b-25 was filed on April 1, 2026. The notice does not immediately affect trading of Aimei’s ordinary shares, rights, or units on Nasdaq, but continued noncompliance could result in delisting.
The company has 60 days from the notice date to either file the annual report or submit a compliance plan, and may receive up to 180 days from the original due date if a plan is accepted. Aimei states it is working diligently to complete and file the Form 10-K and expects to regain compliance.
Aimei Health Technology Co., Ltd reported that Nasdaq notified the company on April 17, 2026 that it is out of compliance with Nasdaq Listing Rule 5250(c)(1) because it has not filed its Form 10-K for the year ended December 31, 2025. The report was due March 31, 2026, and a Form 12b-25 was filed on April 1, 2026. The notice does not immediately affect trading of Aimei’s ordinary shares, rights, or units on Nasdaq, but continued noncompliance could result in delisting.
The company has 60 days from the notice date to either file the annual report or submit a compliance plan, and may receive up to 180 days from the original due date if a plan is accepted. Aimei states it is working diligently to complete and file the Form 10-K and expects to regain compliance.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination with United Hydrogen Group Inc. by one month, moving the termination date from March 6, 2026 to April 6, 2026. To fund this sixteenth extension, a total of $34,330.96 was deposited into the company’s trust account for public shareholders, calculated as the lesser of $80,000 for all outstanding public shares or $0.033 per outstanding public share for the month.
In connection with the extension, the company issued an unsecured promissory note for $34,330.96 on March 4, 2026 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $17,165.48. The note bears no interest and becomes due when the business combination with United Hydrogen is completed. The payees may convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-fifth of one ordinary share, if they notify the company at least two business days before the business combination closes.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination with United Hydrogen Group Inc. by one month, moving the termination date from March 6, 2026 to April 6, 2026. To fund this sixteenth extension, a total of $34,330.96 was deposited into the company’s trust account for public shareholders, calculated as the lesser of $80,000 for all outstanding public shares or $0.033 per outstanding public share for the month.
In connection with the extension, the company issued an unsecured promissory note for $34,330.96 on March 4, 2026 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $17,165.48. The note bears no interest and becomes due when the business combination with United Hydrogen is completed. The payees may convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-fifth of one ordinary share, if they notify the company at least two business days before the business combination closes.
Aimei Health Technology Co., Ltd has extended the deadline to complete its initial business combination by one month, moving the termination date from February 6, 2026 to March 6, 2026. To fund this fifteenth monthly extension, an aggregate $34,330.96 was deposited into the company’s trust account for public shareholders.
In connection with this extension, the company issued an unsecured promissory note for $34,330.96 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., each contributing $17,165.48. The note bears no interest and becomes payable when the company consummates its proposed business combination with United Hydrogen. The payees may instead convert the note into private units of Aimei Health at $10.00 per unit immediately before closing, with each unit consisting of one ordinary share and a right to receive one-fifth of one ordinary share.
Aimei Health Technology Co., Ltd has extended the deadline to complete its initial business combination by one month, moving the termination date from February 6, 2026 to March 6, 2026. To fund this fifteenth monthly extension, an aggregate $34,330.96 was deposited into the company’s trust account for public shareholders.
In connection with this extension, the company issued an unsecured promissory note for $34,330.96 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., each contributing $17,165.48. The note bears no interest and becomes payable when the company consummates its proposed business combination with United Hydrogen. The payees may instead convert the note into private units of Aimei Health at $10.00 per unit immediately before closing, with each unit consisting of one ordinary share and a right to receive one-fifth of one ordinary share.
Mizuho Financial Group, Inc. has filed Amendment No. 3 to its Schedule 13G stating that it now beneficially owns 0 common shares of Aimei Health Technology Co., Ltd., representing 0.0% of the common share class as of 12/31/2025.
The filing reports no sole or shared voting or dispositive power over Aimei’s common shares. Mizuho is identified as a parent holding company, and notes that related entities may have been indirect beneficial owners through a wholly owned subsidiary, Mizuho Securities USA LLC.
Mizuho Financial Group, Inc. has filed Amendment No. 3 to its Schedule 13G stating that it now beneficially owns 0 common shares of Aimei Health Technology Co., Ltd., representing 0.0% of the common share class as of 12/31/2025.
The filing reports no sole or shared voting or dispositive power over Aimei’s common shares. Mizuho is identified as a parent holding company, and notes that related entities may have been indirect beneficial owners through a wholly owned subsidiary, Mizuho Securities USA LLC.
Aimei Health Technology Co., Ltd deposited $150,000 into its trust account to extend the deadline to complete its initial business combination by one month, moving the termination date from September 6, 2025 to October 6, 2025. This is the tenth of up to 12 one‑month extensions allowed under its current Articles of Association.
To fund this extension, the company issued a $150,000 unsecured promissory note on September 5, 2025 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $75,000. The note bears no interest and becomes due when the company completes a business combination with United Hydrogen. The payees may instead convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one‑fifth of one ordinary share, immediately before the business combination closes.
Aimei Health Technology Co., Ltd. completed a $69.0 million initial public offering of 6,900,000 Units and a $3.32 million private placement, placing $73,784,549 in a U.S. trust account invested in short-term Treasuries or qualifying money market funds until a business combination closes or funds are distributed to redeeming public shareholders. As of December 31, 2024, the company held $28,208 of cash outside the trust, reported a working capital deficit of $747,377 and a shareholders' deficit presentation reflecting 6,900,000 shares subject to redemption at $10.10 per share. The registrant recorded $31.27 million of redemptions of 2,904,267 shares and made multiple $150,000–$227,700 monthly extension deposits into the trust to extend the combination period. The filing discloses the company has not adopted a formal cybersecurity risk management program and notes reliance on third-party technologies and limited resources to investigate or remediate cyber vulnerabilities.
Aimei Health Technology Co., Ltd. completed a $69.0 million initial public offering of 6,900,000 Units and a $3.32 million private placement, placing $73,784,549 in a U.S. trust account invested in short-term Treasuries or qualifying money market funds until a business combination closes or funds are distributed to redeeming public shareholders. As of December 31, 2024, the company held $28,208 of cash outside the trust, reported a working capital deficit of $747,377 and a shareholders' deficit presentation reflecting 6,900,000 shares subject to redemption at $10.10 per share. The registrant recorded $31.27 million of redemptions of 2,904,267 shares and made multiple $150,000–$227,700 monthly extension deposits into the trust to extend the combination period. The filing discloses the company has not adopted a formal cybersecurity risk management program and notes reliance on third-party technologies and limited resources to investigate or remediate cyber vulnerabilities.
Aimei Health Technology Co., Ltd is a blank check company formed to complete an initial business combination and has not commenced operations. The company holds the majority of its proceeds in a trust for public shareholders, reporting $2,138 in cash, $44,511,399 in its Trust Account and total assets of $44,556,037. Ordinary shares subject to possible redemption totaled 3,995,733 at a redemption value of $11.14, and total shareholders' deficit was $(2,859,328).
For the six months ended June 30, 2025 the company reported net income of $609,632, driven by interest on trust assets of $1,064,650 offset by formation and operating costs of $455,018. The company amended and extended its combination period multiple times (now extended to September 6, 2025), issued extension promissory notes totaling $1,205,400 as of June 30, 2025, and redeemed 2,904,267 shares for approximately $31.27 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern if it fails to complete a business combination within the prescribed period.
Mizuho Financial Group reports beneficial ownership of 550,600 common shares of Aimei Health Technology, representing 9.0% of the outstanding class. The filing states Mizuho has sole voting and dispositive power over these shares and that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
The filing is made by the parent holding company and discloses that related entities (Mizuho Bank, Mizuho Americas LLC) may be deemed indirect beneficial owners through a wholly owned broker-dealer subsidiary.